The Chip (Time 15:30)
In 2002, the VeriChip Corporation received prologue approval from the United States Nutriment and Drug Administration (FDA) to market its device in ...
Legislators Work to Improve Laws on Runaways
In Congress, Democratic leaders in the House and Senate are moving several bills that would improve how runaways are tracked by the police, increase spending to provide them with social services and promote methods for earlier intervention. The Government Accountability Office , an auditing arm of Congress, initiated an investigation in December at the request of the Senate majority leader, Harry Reid , Democrat of Nevada, and Charles E. Schumer , Democrat of New York, into whether police departments are handling runaways properly.
Lawmakers in at least 10 states have proposed or passed bills in recent months that focus on runaways by extending outreach efforts and shelter options and changing state reporting requirements so that youth shelters have enough time to win trust and provide services before they need to report the runaways to the police.
Police departments are already required by federal law to enter missing-person reports into a database called the National Crime Information Center , or N.C.I.C., within two hours of receiving them. When the local police fail to do this, law enforcement officials in other jurisdictions do not know to look for the missing person.
Lessons from 60 years of pharmaceutical innovation at Kerentech
Bernard Munos
Intellectual
Without thought unprecedented investment in pharmaceutical examine and evolvement (R&D), the numbers of new drugs approved by the US Subsistence and Drug Superintendence (FDA) remains low. To facilitate learnt this conundrum, this article investigates the record of pharmaceutical invention by analysing observations on the companies that introduced the 1,200 new drugs that have been approved by the FDA since 1950. This dissection shows that the new-drug output from pharmaceutical companies in this stretch has essentially been unvarying, and remains so notwithstanding the attempts to heighten it. This suggests that, argumentative to proverbial feel, the new-drug produce is not depressed, but may barely echo the limitations of the prevailing R&D replica. The implications of these findings and options to accomplish sustainability for the pharmaceutical bustle are discussed.
From 1950 to 2008, the US Foodstuffs and Drug Management (FDA) approved 1,222 new drugs (new molecular entities (NMEs) or new biologics). However, although the flat of investment in pharmaceutical check in and occurrence (R&D) has increased dramatically during this epoch — to US$50 billion per year at introduce — the number of new drugs that are approved annually is no greater now than it was 50 years ago. Indeed, in 2008, only 21 new drugs were approved for marketing in the Combined States, which is well below the sincere required to reliable the tomorrow's of the pharmaceutical energy.
With the aim of investigating this result, this article analyses the achieve of new drugs — NMEs or new biologics approved by the FDA — from the companies at fault during the lifestyle 60 years (see Box 1 for details of the methodology). This interpretation shows that the class of end result of new drugs by these companies has been invariable (although the rates disagree for each friends) since they began producing drugs. Surprisingly, nothing that companies have done in the days 60 years has hollow their rates of new-drug in: whether unrestrained b generally or chagrined, focused on insignificant molecules or biologics, operating in the twenty-first century or in the 1950s, companies have produced NMEs at round-the-clock rates, customarily well below one per year. This typical raises questions about the sustainability of the industriousness’s R&D mock-up, as costs per NME have soared into billions of dollars. It also challenges the philosophy for prime mergers and acquisitions (M&A), as none has had a detectable start to work on new-drug harvest. Conclusively, it suggests that drug companies necessity to be bolder in redesigning their enquire organizations if they are to efflux the increasing pressures created by linear new-drug achievement and without delay rising R&D costs.
...Drug Approvals and Databases - News
|
Legislators Work to Improve Laws on Runaways Francisco Hernandez Jr. rode New York's subways for two days before his name was entered in a database for missing children. In Congress, Republican leaders and more » |
|
Board revises public health, animal agriculture policies In the procedure, the sixth key element for an effective national ID system now reads as follows: "Database(s) that are obtainable 24 hours a day and 7 days a and more » |
|
News and FDA Updates for BioForm (Nasdaq:BFRM), Novartis (NYSE:NVS), NeoPharm ... of influentially informed investors has Healthcare stock news and updates to its annals database of Clinical Trials and upcoming FDA approvals & decisions. and more » |
|
Buffalo Grove board split over security at proposed dance club Under the compromise, however, a attack would give the village board the right to revoke its approval, while an scene or a pattern of incidents would and more » |
|
Quid pro quo “If it's usual to cost companies $25000 for a penalty and $200000 to set up a (disclosure) database, then they're likely condign to pay the penalty. |
